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1. Introduction 
Chronic prostatitis (CP) refers to "inflammation" of the prostate and is thought to be related 
to either an acute or chronic infection of the prostate gland. It is important to distinguish 
chronic prostatitis / chronic pelvic pain syndrome (CPPS) from other forms of infections of 
the prostate gland which include chronic bacterial prostatitis and acute bacterial prostatitis 
[1]. The aetiology, pathogenesis, and optimal treatment of CP/CPPS continue to be 
evaluated. In addition to an infective and inflammatory pathogenesis hypothesized for 
patients with CP/CPPS, it is important to highlight a variable degree of neuropathic pain. 
We present the current definition, pathogenesis and new treatment methodologies being 
developed to treat CP/CPPS, which continue to be a challenging clinical entity to treat 
worldwide by Urologist. 
2. Definition and classification 
The European Urology Association [EAU] 2010 guidelines use the term "Painful Prostate 
Syndrome (PPS)" instead of the initial terminology by the National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK) of CP/CPPS. PPS or CP/CPSS is defined as PPS is 
persistent discomfort or pain in the pelvic region with sterile specimen cultures and either 
significant or insignificant white blood cell counts in prostate-specific specimens (i.e., 
semen, expressed prostatic secretions, and urine collected after prostate massage) [2]. As 
there are no clinically relevant diagnostic or therapeutic consequences arising from 
differentiating between inflammatory and noninflammatory subtypes, CP/CPPS can be 
regarded as one entity. 
The National Institute of Health (NIH) International Collaborative Prostatitis Network 
developed a prostatitis classification system in 1995, which termed CP/CPPS as ‘Category 
III prostatitis’ defined by its abacterial nature and occurrence with or without prostatic 
inflammation [3, 4]. A summary of this classification is presented in Table 1. 
As per the NIH classification in actual clinical practice, both Type I (Acute Bacterial 
Prostatitis) and Type II (Chronic Bacterial Prostatitis) only account for approximately 5-10% 
of patients [5]. Acute prostatitis is characterized by a sudden onset of fever and dysuria. 
Chronic prostatitis is clinically characterized by recurrent episodes associated with recurrent 
same organism. Patients tend to be asymptomatic in-between episodes of infections.    
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NIH Consensus Clinical descriptor Clinical details 
Type I  
Acute bacterial 
prostatitis 
Severe symptoms of prostatitis, 
symptoms of systemic infection and 
acute bacterial urinary tract infection 
with bacteriuria and pyuria  
Type II 
Chronic bacterial 
prostatitis 
Chronic bacterial infection of the 
prostate gland with or without 
symptoms of prostatitis, usually with 
recurrent UTI's cause by the same 
bacteria 
Type III A 
Inflammatory subtype a 
(CP/CPPS) 
Characterized by chronic pelvic pain 
and possibly voiding symptoms with 
no bacterial infection; leucocytes 
present in expressed prostatic 
secretions or semen 
Type III B 
Non-Inflammatory 
subtype  
Characterized by chronic pelvic pain 
and possibly voiding symptoms with 
no bacterial infection; leukocytes 
present in expressed prostatic 
secretion or semen 
Type IV 
Asymptomatic 
Inflammatory prostatitis  
Evidence of inflammation without 
symptoms of prostatitis or UTI 
aWBC semen > 106/ml, WBC EPS > 5 p hpf, WBC VB3 > 10 p hpf 
Table 1. NIH classification of prostatitis syndromes. 
Type III is classified as CP/CPPS and PPS as per the latest EAU guidelines. Patients within 
this category constitute about 90% of cases and it is hence very important to understand the 
definition of Type IIIA and Type IIIB categories. Type IIIA refers to the presence of white 
blood cells (WBC) in semen, after a prostate massage urine specimen (VB3) or expressed 
prostatic secretion (EPS). Type IIIB refers to patients with pelvic pain with no evidence of 
inflammation on semen, VB3 or EPS. 
Type IV patients are asymptomatic  and are commonly diagnosed during work up for 
infertility and lower urinary tract symptoms  (LUTS) where they have an elevated PSA. In 
the MTOPS study, there is a strong link between prostatic inflammation to increased LUTS 
or the risk of acute urinary retention in a cohort of BPH subjects [6]. This may suggest that 
Type IV prostatitis may not be "asymptomatic" after all.  
3. Epidemiology 
Prostatitis is a significant health problem with prevalence rates of 11-16%.[7,8] More than 2 
million consultations for prostatitis are required every year in the United States[9]. 
Prostatitis has a significant impact on the quality of life (QoL) comparable to active Crohn's 
disease or a recent myocardial infarction.[10] with up to 50% of men affected by it at some 
stage of their lives.[11,12]. 
In a large recent review by Krieger et al [13], the prevalence of prostatitis symptoms in 
10,617 men was 8.2% (873). Amongst these patients the prevalence of prostatitis symptoms 
ranged from 2.2% to 9.7%, with a median rate of 8.7%.  
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Prostatitis-like symptoms result in a substantial number of physician visits. Sixty percent of 
participants with prostatitis-like symptoms seek medical help [13, 14]. The odds of a 
prostatitis diagnosis is 13-fold greater during visits to urologists than during visits to 
primary care physicians [15].  Additionally, patients with prostatitis tend to receive 
antimicrobials therapy in 45% of cases compared to 27% of the time for patients with no 
genitourinary symptoms [15]. Men with prostatitis symptoms appear to be at increased risk 
for persistent symptoms and for recurrent episodes.  Although the pathogenesis of prostates 
is still being evaluated, it is common in clinical practice to see patients recurrently with 
acute episodes of prostatitis with a background of chronic prostatitis. These patients hence 
have a substantially higher cumulative probability of subsequent episodes of prostatitis [16]. 
4. Pathogenesis 
The aetiology and pathophysiology of CP/CPPS remains a mystery, although central 
neurological mechanisms probably play a role. Patients with PPS show no evidence of 
infection; they do not have urethritis, urogenital cancer, urethral stricture, or neurologic 
disease involving the bladder, and they do not exhibit any overt renal tract disease [17]. 
Hence, the exact aetiology of CP/ CPPS is unknown. The main factor that continues to be 
evaluated in patients with CP / CPPS is whether infection and inflammation are responsible 
for the clinical symptomology of these patients. The difficulty in pinpointing etiologic 
mechanisms and obtaining efficacious therapies is probably due to the heterogeneity of 
factors that contribute to CP/CPPS. Despite this complexity, most experts agree that pain is 
the defining feature of the condition.  
The initial concept of infection and inflammation arose when True et al [18], analyzed the 
outcome of Prostate histopathology in 368 biopsies from 97 patients with the CP/CPPS. In 
these patients prostatic inflammation was detected in only 33% of patients, including 29% 
with mild (less than 10 leukocytes per 1 mm. field) and 4% with moderate (between 10 and 
200) or severe (more than 200) infiltrate. Of the 3 patients with moderate inflammation 1 had 
glandular, 1 periglandular and 3 multifocal or diffuse distribution of leukocytes in the 
interstitium. Although 33% of patients had inflammation on prostate biopsies, only 5% of 97 
patients had moderate to severe inflammation. This study questioned the assocaition and 
role of inflammation in the pathogenesis of CP/CPPS. Despite this CP/CPPS continues to be 
diagnosed on the basis of symptoms. It is diagnosed from a history of persistent 
genitourinary pain and an absence of other lower urinary tract pathologies. The severity of 
disease, its progression and treatment response can be assessed only by means of a 
validated symptom-scoring instrument [19, 20]. 
Patients with CP/CPPS are diagnosed traditionally using the gold-standard four-glass test 
for bacterial localisation [21]. However, as this test is cumbersome to perform and hence the 
diagnostic efficiency may be enhanced cost effectively by a simple screening procedure, that 
is, the two-glass test, or by pre- and post-massage test (PPMT) [22], with PPMT able to 
indicate the correct diagnosis in >96% of patients [23]. These tests use the concept of White 
blood cells (WBC) as a marker on inflammation. White blood cells can be found in seminal 
plasma and prostatic fluid of asymptomatic patients and in patients with pelvic pain [24]. 
Schaeffer et al [24], examined whether leukocytes and bacteria correlate with symptom 
severity in men with chronic prostatitis/chronic pelvic pain syndrome. In this landmark 
publication, 488 men were classified into the CP/CPPS criteria NIH criteria. Participants 
were classified as category IIIa based on WBC counts of 5 or more, or 10 or more (5+, 10+) in 
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the expressed prostatic secretion, or 1+ or 5+ either in the post-expressed prostatic secretion 
urine (voided urine 3) or semen. Uropathogens were classified as localizing if the designated 
bacterial species were absent in voided urine 1 and voided urine 2 but present in expressed 
prostatic secretion, voided urine 3 or semen, or present in expressed prostatic secretion, 
voided urine 3 or semen at 2 log concentrations higher than at voided urine 1 or 2. 
Associations between symptoms and inflammation and infection were investigated using 
generalized Mantel-Haenszel methods. Of all participants 50% had urethral leukocytes and 
of 397 with expressed prostatic secretion samples 194 (49%) and 122 (31%) had 5+ or 10+ 
WBCs in expressed prostatic secretion, respectively. The prevalence of category IIIa ranged 
from 90% to 54%, depending on the composite set of cut points. None of the index measures 
were statistically different (p >0.10) for selected leukocytosis subgroups. Based on prostate 
and semen cultures, 37 of 488 men (8%) had at least 1 localizing uropathogen. None of the 
index measures were statistically different (p >0.10) for selected bacterial culture subgroups. 
The authors thus concluded that men with chronic prostatitis routinely receive anti-
inflammatory and antimicrobial therapy despite leukocytes and bacterial counts which do 
not correlate with severity of symptoms. These findings suggest that factors other than 
leukocytes and bacteria also contribute to symptoms associated with chronic pelvic pain 
syndrome.  
Based on current studies the initiator of the inflammatory process in CP / CPPS within the 
prostate is thought to be a local infection, chemical irritation, dysfunctional voiding, 
intraductal reflux, neuromuscular disturbances or an immunological process. Regardless of 
the triggering factor, the resultant inflammatory process causes tissue oedema and increased 
intra-prostatic pressure leading to local hypoxia and varied mediator-induced tissue 
damage. This leads to altered neurotransmission in sensory nerve fibres thereby resulting in 
the pain and other symptoms associated with the condition [25]. We now present each 
aetiology associated with CP / CPPS. 
The common etiologies associated with CP / CPPS include 
- 4A. Infection  
- 4B. Inflammation and Autoimmunity 
- 4C. Neurological  
- 4E. Psychological  
- 4F. Additional Conditions 
4A. Infection 
An acute episode of prostatitis and recurrent episodes of chronic prostatitis can be caused 
by organisms that are commonly responsible for Urinary Tract Infections (UTI). The 
majority of organisms isolated within both patients groups include Escherichia coli in the 
community. Additionally bacteria responsible for both acute and chronic prostatitis include 
Pseudomonas and Streptococcus faecalis. The symptoms of CP / CPPS are identical to those of 
prostatic infection. Pontari et al [26], conducted a questionnaire to evaluate the 
demographic, behavioural, clinical and medical history characteristics of men with chronic 
prostatitis/chronic pelvic pain syndrome (CP/CPPS) and asymptomatic controls. In their 
study they analyzed the outcome of 463 men with CP/CPPS and 121 asymptomatic age-
matched controls. Interestingly, compared to controls, men with CP/CPPS reported a 
significantly greater lifetime prevalence of nonspecific urethritis (12% vs 4%, P = 0.008), 
cardiovascular disease (11% vs 2%, P = 0.004), neurological disease (41% vs 14%, P < 0.001), 
psychiatric conditions (29% vs 11%, P < 0.001), and haematopoietic, lymphatic or infectious 
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disease (41% vs 20%, P < 0.001). Hence, the outcome of this publication suggested that a 
range of self-reported medical conditions are associated with CP/CPPS with a higher 
proportion reporting a history of nonspecific uretheritis caused due to gonorrhoeal, 
trichomonal and henital herpetic infections. It was also suggested that rare episodes of 
recurrent cystitis in young males is caused due to secondary infections of the prostatic ducts. 
An important factor associated with recurrent infections in CP is ascending urethral 
infection and reflux of urine into ejaculatory and prostatic ducts [27]. Bacteria can be 
isolated preferentially from an expressed prostatic secretion (EPS) or a post-prostatic 
massage urine specimen rather than from the mid-stream urine (MSU) sample or can be 
demonstrated on the prostatic biopsy specimen [28,29]. The concept of intraprostatic reflux 
was demonstrated by Kirby et al [30]. In this publication the authors injected carbon 
particles into the bladders of men about to undergo a transurethral resection of prostate 
(TURP). On histological analysis of the resected TURP specimen, carbon particles could be 
demonstrated which suggested a intraprostatic reflux.   
Blacklock et al [31], noted that some patients with CP / CPPS had some pathogens identified 
in vaginal cultures of their sexual partners. Magri et al [32], evaluated 55 symptomatic 
patients with CP / CPPS they were subjected to segmented tests to localise Chlamydia 
trachomatis in first voided urine (VB1), prostatic secretions (EPS), post-massage voided 
(VB3) or semen specimens. Patients were divided in three treatment groups: the 'urethral 
involvement' group (VB1 positive, EPS/VB3/Semen negative) was treated with 500 mg 
day(-1) azithromycin for 3 days. The 'prostatitis' group (VB1 negative, EPS/VB3/semen 
positive) with 4-week levofloxacin-azithromycin combination. A third group, 'Urethral and 
Prostate group' (VB1, EPS/VB3/semen positive) received both treatments in sequence. In 
patients prosatitis, eradication of Chlamydia trachomatis was paralleled by marked, 
sustained symptom improvement and by significant decrease of serum prostate-specific 
antigen (PSA) levels. Compared with Urethral  patients, undergoing rapid regression of 
symptoms related to painful micturition after short-term azithromycin, U+P patients 
showed symptom and pathogen persistence in VB3/EPS/semen and required additional 
treatment with 4-week levofloxacin-azithromycin to achieve pathogen eradication, symptom 
regression, and decrease of PSA. The results from this publication support a causative role 
of Chlamydia trachomatis in CP / CPPS. 
Mardh et al [33], evaluated the role of Chlamydia trachomatis in non-acute prostatitis was 
investigated by cultural and serological techniques in a study of 53 adult males. C. 
trachomatis was isolated from the urethra of only one of the 53 patients and from none of 
the 28 specimens of prostatic fluid from the same patients. By means of a modified 
microimmunofluorescent test, serum chlamydial IgG antibodies at a titre of 1/64 or greater, 
or IgM antibodies at a titre of 1/8 or greater, or both were detected in six of the patients, 
suggesting a recent or current chlamydial infection, while IgG or IgA antibodies at a titre of 
1/8 or greater were detected in the specimens of prostatic fluid from two of the 28 men 
studied. In the seven patients with evidence of chlamydial infection, as well as in a further 
13 of the 53 patients studied, the presenting symptoms suggested non-gonococcal urethritis 
(NGU) rather than prostatitis. Thus in this study, C. trachomatis would appear to play a 
minor aetiological role, if any, in CP / CPPS. 
Based on current literature and evidence, there continues to be inconsistencies in the 
response to antibacterial treatment and the inability to consistently isolate any pathogenic 
organisms in the appropriate specimens in patients with CP / CPPS.  
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4B. Inflammation and autoimmunity 
Both acute and chronic inflammation is now thought to be associated with CP / CPPS. The 
core of Inflammation lies with the presence of both pro and anti-inflammatory cytokines 
present with the prostate in comparison to normal asymptomatic patients. The main 
cytokines linked with CP / CPPS are Interleukin - 8 [34], Interleukin - 10 [35] and Tumour 
Necrosis Factor - alpha (TNF-α) [36].  
The concentration of citric acid is a significant parameter of prostate gland function [37]. 
Substantial amounts of citric acid are produced and stored in the gland. A decrease in its 
concentration is observed in cases of inflammation or cancer of the prostate gland [38]. In 
addition to citric acid there is now a new interest in the evaluation of polymorphonuclear 
(PMN) leukocytes and PMN elastase levels in patients with PC / CPPS. Zdrodowska-
Stefanow et al [39], evaluated PMN leukocytes , PMN elastase and citric acid concentrations 
in chronic prostatitis patients regardless of aetiology and in a parallel group with C 
trachomatis infection. In this paper the analysis of expressed prostatic secretions (EPC) of 46 
patients with chronic prostatitis was evaluated for leukocyte count, PMN elastase (ELISA) 
and citric acid concentrations. All patients have an additional analysis for C. trachomatis 
infection (ligase chain reaction). Analysis confirmed increased PMN cell counts (≥10 per 
high-power field) in 73.9% of patients and increased PMN elastase concentration (<250 
ng/ml) in 78.3%. In 44.4% of the patients the elastase concentration indicated moderate 
(250–1000 ng/ml) and in 55.6% acute infection (≥1000 ng/ml). Decreased citric acid 
concentration (<18.12 mg/ml) in the EPS was found in 65.2% of the men. C. trachomatis 
prostate infection was detected in 17.4% of the patients and all of these men had higher 
inflammation parameters and lower citric acid concentrations. The authors concluded that 
CP /CPSS associated with C. trachomatis infection were accompanied by an increase in 
inflammation markers and a decrease in citric acid concentration.  
Autoimmunity is characterized by recognition of self by the immune system with the 
resulting immune response destroying or damaging normal cells and tissues. T lymphocytes 
are principally responsible for the recognition of antigens by the immune system. CD4 T 
cells recognize processed peptide antigens in association with the MHC class II molecule 
and play a significant role in the effector function of CD8 T-cells and B-cell activation. In 
previous work we have shown that soluble components in normal semen can be recognized 
by CD4 T lymphocytes in men with CP/CPPS [40, 41]. The current concept of autoimmunity 
is best recognized in patients with non-specific granulomatous prostatitis (NSGP). Within 
this group of patients it is the HLA class II allele DRB1*1501 in Caucasian men is associated 
with CP/CPPS [42].  
In a landmark paper evaluating the link between autoimmunity and CP / CPPS, 
Kouiavskaia et al [40], aimed to assess whether T cells from a group of men with CP/CPPS 
would recognize peptides derived from the normal self prostatic proteins prostate specific 
antigen (PSA) and prostatic acid phosphatase (PAP).  The authors used purified CD4 T cells 
from the peripheral blood of 31 patients with CP/CPPS and from the buffy coat preparation 
of 27 normal male blood donors that were stimulated in vitro with a panel of immunogenic 
peptides from PSA and PAP and assayed for reactivity with the peptides by IFN-γ ELISPOT 
assay. The data from this study suggested that the peptides such as PAP133-152, PAP173-192, 
PSA171-190, PSA221-240 represent promiscuous epitopes able to be presented by different HLA-
DR alleles. High level of the peptides promiscuity was supported by the results of both 
analysis of MHC class II allele expression by the individuals responding to the peptides in 
www.intechopen.com
 
Chronic Prostatitis / Chronic Pelvic Pain Syndrome 
 
207 
the IFN-γ ELISPOT assay and analysis of the direct binding of the peptides to MHC class II 
molecules. In vitro functional assays showed that autoreactive T cells specific for the 
peptides are present and can be activated in the patients with CP/CPPS and normal male 
blood donors, identified PAP as a possible target protein for autoimmune reactivity in the 
patients with CP/CPPS and demonstrated that autoimmune reactions to the 
immunodominant peptide PAP173-192 might be involved in the disease development. The 
data supported autoimmunity as a potential aetiology for CP/CPPS in some patients and 
suggest that immunosuppressive therapies might logically be tested in the treatment of this 
complex and frustrating disorder. The authors found that Peptide PAP173-192 was more 
frequently recognized by CD4 T cells from the patients with CP/CPPS compared to the 
healthy donors. Peptide reactivity was more commonly observed in cases compared to 
normal male blood donors for any PSA peptide or any tested peptides. This study 
demonstrated a strong link between autoimmunity and CP / CPPS in that CD4 T cells from 
patients with CP/CPPS had a higher frequency of recognition of the self prostatic proteins 
PAP and PSA compared to normal male blood donors.   
4C. Neurological  
CP/CPPS is associated with the patient developing pain and this suggests a possible 
neurological link with the diagnosis. The pain perceived by these patients can be a 
combination of either local pain within the pelvis or more central pain. Hence, one further 
hypothesis in the development of CP/CPPS includes dysfunction of the nervous system that 
attributes to the patients symptoms. Despite attributing a strong neurological link few of the 
agents that have been studied in clinical trials target pain pathways directly, particularly 
those in the central nervous system (CNS). Recent animal model studies on retrograde 
labelling of the prostate and pelvic floor indicates that there are double labelled cells in the 
dorsal root ganglion in the lumbar and sacral cord [42]. Patients with CPPS are thought to 
have an altered sensation of the perineum in comparison to control patients without 
CP/CPPS. The mechanism of this 'altered' innervations is poorly understood and is thought 
to be related to reflex sympathetic dystrophy of the perineum and pelvic floor [43-45]. 
4E. Psychological  
Psychological stress is also commonly associated with the exacerbation of  symptoms related 
to CP/CPPS. The initial evidence of a strong psychological link was after Wallner et al [46], 
collected data from 703 men enrolled in the Flint Men’s Health Study, a population-based 
health study of African American men. Participants were interviewed about their health 
history and lifestyle factors, such as physical activity. They also answered questions about 
stress and emotional health. In this study poor emotional health, high levels of stress (as 
perceived by study participants), and a lack of social support were associated with a history 
of CP. The findings were consistent with a previous study by Collins et al [47], which also 
reconfirmed that patients with severe stress at work or home were 1.2 and 1.5 times more 
likely to report CP, respectively, than those whose lives were relatively stress-free. 
Ullrich et al [48], associated stress to be an important factor responsible for the development 
of CP/CPPS. In this study , 200 men were interviewed about the level of stress and degree 
of pain intensity by telephone a month after the men were diagnosed with CP and then 
again three, six, and 12 months later. This publication concluded that the men with more 
perceived stress during the six months following diagnosis were in more pain after a year 
than those who experienced less stress. Despite the limitations of the study, such as the lack 
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of health data on participants prior to diagnosis, the paper concluded that treatment in 
patients with CP / CPPS should include stress management techniques.  
4F. Additional health conditions  
Additional health conditions associated with CP / CPPS include - Irritable bowel syndrome, 
Fibromyalgia and chronic fatigue syndrome .  
5. Diagnosis 
There is no gold standard for diagnostic testing for the CPPS [49]. The 4-glass or 2-glass test 
may provide information on prostatic inflammation (e.g., the number of white cells per 
high-power field), but this finding is not helpful in the diagnosis or management of the 
condition. Among men with presumed chronic pelvic pain syndrome and no history of 
urinary tract infection, up to 8% have been found to have positive prostatic localization 
cultures, but these findings have also been reported in a similar percentage of asymptomatic 
men [50].  
The current EAU 2008 guidelines highlight that CP/CPPS is more of a symptomatic 
diagnosis. To facilitate in the diagnosis the following an initial sterile pre-massage urine 
(voided bladder urine-2 [VB2]) is collected, patient with CP/CPPS shows less than 10,000 
colony-forming units of uropathogenic bacteria in expressed prostatic secretions (EPS) and 
insignificant numbers of leucocytes or bacterial growth in ejaculate. Diagnostic efficiency 
may be enhanced cost-effectively by a simple screening procedure, i.e. the two-glass test or 
pre-post-massage test (PPMT) [49]. In an extensive analysis of both tests, PPMT was able to 
indicate the correct diagnosis in more than 96% of patients [50]. 
Additional tests performed to facilitate diagnosis include a flowrate studies, urodynamic 
assessments and a transrectal ultrasound to exclude an obstructed seminal vesicle. A 
transrectal ultrasound is indicated in patients with CP/CPPS and painful ejaculation. In 
these patients a transrectal ultrasonography may reveal enlargement of the seminal vesicle 
caused by obstruction of the ejaculatory duct; such an obstruction may be associated with or 
exacerbate the chronic pelvic pain syndrome. Isolated case reports suggest that the 
correction of the obstruction may relieve pain, although this cannot be proved because of a 
lack of data [51]. A urodynamic assessment can be performed when patients have 
concomitant lower urinary tract symptoms that are refractory to treatment. 
To assess the accurate symptomology at the time of diagnosis it is essential for patients tom 
complete the The NIH Chronic Prostatitis Symptom Index. This 9 item, self-administered 
tool leads to the development of a score between is 0 to 43 points [52]. A summary of the 
current investigations from our department based on current European Association of 
Urology guidelines summarized in Figure 1. 
6. Treatment 
The treatment of CP/CPPS continues to be challenging. We divide the Urological treatment 
into Medical and Surgical categories. 
6A. Urological medical treatment 
Effective treatment for the CP/CPPS remains uncertain. Factors complicating the 
management of this condition include its probably multifactorial pathogenesis, lack of a 
gold standard for diagnostic testing, and the methodological limitations of many treatment  
www.intechopen.com
 
Chronic Prostatitis / Chronic Pelvic Pain Syndrome 
 
209 
 
Fig. 1. Our departments guidelines for the initial investigating patients with CP/CPPS. 
studies. Most current treatment strategies focus on symptomatic relief. Despite of numerous 
advocated strategies and new drugs being developed, the US Preventive Services Task Force 
system best summarizes current treatments for CP/CPSS as grade 1 which is defined as 
"drug therapy where current evidence is insufficient to assess the balance of benefits and 
harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of 
benefits and harms cannot be determined." 
The predominant medical treatment of drugs include:- 
1. Antibiotics 
2. Alpha blockers 
3. Anti-inflammatories 
4. 5 α reductase inhibitors 
5. Pentosulphan Polyphosphate 
6. Additional therapies [Physical therapy, Myofascial and trigger point therapy] 
The current mechanism of action and evidence to support the above mentioned treatment is 
summarized in Table 2.  
The Urological Surgery Treatment in patients with CP/CPPS include 
1. Prostatic Massage 
2. Transurethral Microwave therapy 
3. Transurethral resection of prostate 
 
 
Patient history, 
Symptoms score 
[NIH], Digital rectal 
examination, Urine 
culture, baseline PSA 
 
 
Uroflow and post 
micturation residual 
volume 
Definitive indications 
1. Men > 50 years 
 
 
Abbreviated four glass 
test 
1. PPMT [Pre-post-
massage test] 
 
 
Further specific 
investigations 
1. Urodynamics 
2. Transrectal 
ultrasound 
www.intechopen.com
 
Clinical Management of Complicated Urinary Tract Infection 
 
210 
Drug Mechanism of action 
Evidence for 
treatment/Recommended 
agents 
Side effects 
1. Antibiotics Reduces and cures 
infections. This further 
reduces inflammation 
and hence improves 
symptoms of 
CP/CPPS. 
A. Levofloxacin in 80 patients 
for 6 weeks. Outcome - 6 
point decrease in NIH 
symptoms [53] 
B. Ciprofloxacin in 196 
patients for 4-6 weeks. 
Outcome - Significant 
symptomatic improvement 
[54] 
 
A. Side effects of 
fluroquinolones 
including central 
nervous system 
(CNS) toxicity, 
phototoxicity, 
cardiotoxicity, 
arthropathy, and 
tendon toxicity. 
B. RCTs have  
failed to show 
significant 
beneficial effects of 
antibiotics 
compared to 
placebo in patients 
who have already 
failed antibiotic 
treatment 
2. Alpha blockers Inhibit neurological 
activation induced by 
sympathetic 
overactivation 
A. Meta-analysis of treatment 
with Alpha blockers in men 
with CP/CPPS showed 
significant reduction in 
symptoms over a duration of 
3 months [55]. 
 Adverse effects of 
alpha-blockers 
include dizziness, 
fatigue, 
hypotension and 
decreased ejaculate 
volume  
3. Anti-
inflammatories 
Reduce systemic or 
prostatic inflammation, 
autoimmunity, CNS 
transmission of pain 
signals, and central 
sensitization 
 
A. Main symptom of 
CP/CPPS is pain. Hence, it is 
very important to control this 
symptom. 
B. Tricyclic Antidepressants 
are widely used for pain and 
act by inhibiting central 
neuronal reuptake of 
Norepinephrine and 
Serotonin. Both substances 
linked to pain. 
C. Current medication 
recommenced includes - 
Gabapentin, Pregabalin and 
Amitriptyline 
D. COX 2 inhibitors are now 
being investigated as these 
drugs regulate prostaglandin 
production. In an RCT of the 
COX2 inhibitor rofecoxib, the 
NIH-CPSI total and pain 
scores showed improvement 
in the rofecoxib group, but the 
difference between rofecoxib 
and placebo was not 
statistically significant [56]. 
Adverse effects of 
Tricyclic include 
dry mouth, dry 
nose, and increased 
body temperature. 
Other side effects 
may include 
drowsiness, 
anxiety, akathisia, , 
tachycardia. 
Twitching, 
hallucinations, 
delirium and coma 
are also some of the 
toxic effects caused 
by overdose. 
Rhabdomyolysis or 
muscle breakdown 
has been rarely 
reported. 
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Drug Mechanism of action 
Evidence for 
treatment/Recommended 
agents 
Side effects 
4. 5 α reductase 
inhibitors 
 
Reduction in prostatic 
volume 
A. One randomized, placebo-
controlled trial of Finasteride 
showed that scores on the 
Prostatitis Symptom Severity 
Index and the International 
Prostatitis Symptom Survey 
decreased significantly after 1 
year of treatment, but pain 
scores did not change 
significantly [57]. 
B. Response rates at 6 months 
(defined as an improvement 
of more than 25% in scores on 
the NIH Chronic Prostatitis 
Symptom Index) were not 
significantly better for 
Finasteride than for placebo 
(33% vs. 16%) [58]. 
Adverse effects of 5 
α reductase 
inhibitors include 
impotence, 
decreased libido, 
and decreased 
ejaculate volume. 
Rare side effects  
include breast 
tenderness and 
enlargement. 
5. Pentosulphan 
Polyphosphate 
Replenish the 
glycosaminoglycan 
layer of the bladder, 
stabilize prostatic 
stromal mast cells 
 
CP/CPPS is thought to be 
related conditions, and 
Pentosan Polysulfate has been 
tested in an RCT for CP/CPPS . 
The results showed some 
clinical benefit in the 
treatment arm, but the change 
in total NIH-CPSI score was 
not statistically significant 
[59]. 
Pentosan 
Polysulfate has 
minimal side effects 
and is well 
tolerated. 
6. Additional 
therapies 
[Physical 
therapy, 
Myofascial and 
trigger point 
therapy 
Reduce pelvic floor 
muscle dysfunction 
A. Physical therapy, 
Myofascial therapy and 
trigger point therapy reduce 
symptoms related to 
CP/CPPS. 
B. A recent study has 
demonstrated a statistically 
significant improvement in 
symptoms in the patients 
receiving myofascial therapy 
for CP/CPPS in comparison 
to the pharmacological 
medication mention in 
category 1-3. 
None reported 
Table 2. Urological Medical Treatment of CP/CPPS. 
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6B. Urological Surgery Treatment 
The latter two treatments have side effects including reterograde ejaculation and erectile 
dysfunction. These must be highlighted to patients being offered Urological Surgery for 
medically refractory CP/CPPS which continues to be a clinically challenging category of 
patients to manage.  
1. Prostate Massage 
The rationale of this procedure is to try to expel dense prostatic secretion and/or to force an 
obstructed outlet duct. In order to avoid damage to the integrity of a prostatic acinus which 
could lead to worsening of the inflammation, it should be done with care, and in my 
opinion, not before the patient has had hot baths and drugs for a couple of days. It seems 
very helpful in those patients in whom TRUS has shown a sectorial oedema in the prostate. 
In my experience, patients with massive calcifications in the veru-region are rarely helped 
by this manoeuvre; this seems understandable, as those calcifications cannot be removed by 
massage, but, on the contrary, manipulation can traumatize this area and worsen the 
situation. I see my patients 2-3 times a week for a total of about 6-8 sessions.  
2. Transurethral Microwave therapy 
Transurethral microwave thermotherapy, which is widely available, can achieve 
temperatures of more than 45°C within prostatic tissue. One small randomized trial (20 
patients) suggested that transurethral microwave thermotherapy significantly improved the 
quality of life at 3 months, as compared with sham treatment [61]; four patients reported 
transient adverse effects, including hematuria, urinary tract infection, impotence, urinary 
retention, urinary incontinence, and premature ejaculation, but whether these patients 
received active or sham treatment was not stated. 
3. Transurethral Resection of Prostate 
Transurethral resection of the prostate (TURP) is advocated for CP/CPPS based on a few 
anecdotal experiences, but there are absolutely no reliable data or experiences to 
substantiate a treatment effect [62]. Patient with significant lower urinary tract symptoms 
with a background of CP/CPPS may benefit from this therapy. 
7. Conclusion 
Chronic Prostatitis / Chronic Pelvic pain syndrome continues to be a challenging clinical 
entity for urologists. A thorough clinical evaluation and organizing appropriate clinical 
investigations are essential to establish a potentially treatable cause, although this is not 
found in all patients. With new avenues of autoimmunity and inflammation being explored 
as a strong link in the pathogenesis of CP/CPPS, we envisage that this may well direct 
future treatment strategies. However, based on current clinical practice a combination of 
treatment trial including newer biomarkers, genomic, immunological, imaging studies, 
epidemiologic and symptom-based assessments, will maximize the ability to identify an 
effective treatment strategy in the future. 
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